Vertex and Covid-19 spell the end for Savara's CF program
It’s a tough market for cystic fibrosis these days. Just ask Savara.
Two years ago, the Austin-based biotech designed and launched a trial to test whether their lead GM-CSF drug molgradex can reduce lung infection in adult CF patients. At the time, Vertex only had 3 CF drugs, they only covered a portion of patients, and they weren’t always incredibly effective. Then last year came Trikafta, the expensive triple-combination that had significant benefits for around 90% of patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
